{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:21Z","timestamp":1774566441789,"version":"3.50.1"},"reference-count":13,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICI) have transformed cancer therapy but can induce a spectrum of endocrine complications. Acquired generalized lipodystrophy (AGL) is a rare adverse effect, leading to severe metabolic derangements including insulin-resistant diabetes, dyslipidemia, and hepatic steatosis. Marked hypoleptinemia is noted in these patients, and leptin-replacement therapy is known to be beneficial in patients with other forms of AGL. Though rare, T-cell lymphoma has been reported in patients with AGL on leptin therapy, and there has been much debate on the association between hyperleptinemia and cancer. The safety and efficacy of leptin therapy in patients with ICI-induced AGL and cancer are therefore not clear. We report a 66-year-old woman with metastatic lung adenocarcinoma who developed multiple endocrine disorders including AGL with metabolic abnormalities following pembrolizumab therapy. Initiation of daily metreleptin led to marked improvement in dyslipidemia, glycemic control, and hepatic steatosis, with no evidence of cancer recurrence after 2 years of leptin-replacement therapy. While further studies are warranted to establish the long-term efficacy and safety of leptin in ICI-induced AGL patients with a history of malignancy, this case report provides useful information for the management of these rare, challenging patients.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf340","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:58:45Z","timestamp":1766581125000},"source":"Crossref","is-referenced-by-count":1,"title":["Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor\u2013induced Lipodystrophy"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7174-1332","authenticated-orcid":false,"given":"Mona","family":"Vahidi Rad","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhail","family":"Saad-Omer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharath Nair","family":"Suresh Kumar Bindu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-2832","authenticated-orcid":false,"given":"Vinaya","family":"Simha","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"8","key":"2026021521014477900_luaf340-B1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026021521014477900_luaf340-B2","doi-asserted-by":"crossref","first-page":"luad025","DOI":"10.1210\/jcemcr\/luad025","article-title":"Marked hypoleptinemia precedes overt fat loss in immune checkpoint inhibitor\u2013induced acquired generalized lipodystrophy","volume":"1","author":"Dhanasekaran","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"4","key":"2026021521014477900_luaf340-B3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2026021521014477900_luaf340-B4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"2026021521014477900_luaf340-B5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/biom11060913","article-title":"Leptin, both bad and good actor in cancer","volume":"11","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"2026021521014477900_luaf340-B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2026021521014477900_luaf340-B7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr Rev"},{"issue":"11","key":"2026021521014477900_luaf340-B8","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1210\/jc.2015-2589","article-title":"A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin","volume":"100","author":"Lebastchi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026021521014477900_luaf340-B9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"issue":"20","key":"2026021521014477900_luaf340-B10","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1038\/s41388-019-0687-8","article-title":"Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland","volume":"38","author":"Tenvooren","year":"2019","journal-title":"Oncogene"},{"key":"2026021521014477900_luaf340-B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-43093-1_6","article-title":"Leptin in tumor microenvironment","volume":"1259","author":"Angelucci","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2026021521014477900_luaf340-B12","doi-asserted-by":"crossref","first-page":"1582715","DOI":"10.3389\/fendo.2025.1582715","article-title":"A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy","volume":"16","author":"Brown","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"2026021521014477900_luaf340-B13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2019.0463","article-title":"The surprisingly positive association between obesity and cancer immunotherapy efficacy","volume":"321","author":"Murphy","year":"2019","journal-title":"JAMA"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/2\/luaf340\/66904249\/luaf340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/2\/luaf340\/66904249\/luaf340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:01:50Z","timestamp":1771207310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf340\/8484239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf340","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,8]]},"article-number":"luaf340"}}